DRRX DURECT Corporation

0.79
+0.03  (+5%)
Previous Close 0.75
Open 0.78
Price To Book 4.91
Market Cap 127265497
Shares 162,059,718
Volume 236,249
Short Ratio
Av. Daily Volume 432,366

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval announced July 27, 2018.
RBP-7000
Schizophrenia
Phase 2 trial to be initiated 1Q 2019.
DUR-928
Psoriasis
Phase 2 data due 2019.
DUR-928
Primary sclerosing cholangitis (PSC)
CRL issued February 12, 2014.
Posidur
Post-operative pain relief
CRL issued September 26, 2016. NDA refiled but additional CRL issued August 6, 2018. Noted November 12, 2018 that it will meet with the FDA January 31, 2019 to discuss further.
Remoxy
Chronic pain
CRL Feb 12 2014. Phase 3 commenced November 2015 in response to CRL. Noted October 19, 2017 that primary endpoint was not met.
POSIMIR - PERSIST 3
Post-operative pain relief
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Phase 2 trial to be initiated 1Q 2019 with data due 2H 2019.
DUR-928
Nonalcoholic steatohepatitis (NASH)
Phase 2 data due 2019.
DUR-928
Alcoholic hepatitis (AH)

Latest News

  1. Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT — New Research Emphasizes Economic Growth
  2. DURECT Corporation to Participate in the Berenberg NASH Day
  3. Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug
  4. DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications
  5. Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT
  6. DURECT Corporation Provides Corporate Update
  7. Here’s What We Think About DURECT Corporation’s (NASDAQ:DRRX) CEO Pay
  8. DURECT Corporation Announces Investor Call to Provide Corporate Update
  9. Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
  10. DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist
  11. Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE — Research Highlights Growth, Revenue, and Consolidated Results
  12. DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
  13. DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream
  14. Could DURECT Corporation’s (NASDAQ:DRRX) Investor Composition Influence The Stock Price?
  15. Durect: 3Q Earnings Snapshot
  16. DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  17. DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
  18. DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings
  19. DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19564415
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19550478
  3. 8-K - Current report 19542920
  4. 8-K - Current report 19512598
  5. 8-K - Current report 181257699
  6. 8-K - Current report 181242510
  7. 8-K - Current report 181237273
  8. CT ORDER - Confidential treatment order 181227890
  9. 8-K - Current report 181191284
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 181170474